NeoGenomics (NEO) Q4 2025: NGS Revenue Jumps 23% as High-Value Test Shift Reshapes Growth Trajectory
NeoGenomics’ pivot toward higher-margin NGS and MRD testing is accelerating revenue quality and margin expansion, even as non-clinical headwinds persist. The company’s focus on clinical channel penetration and product innovation signals a structural shift in growth drivers, with 2026 guidance embedding upside from new launches and operational leverage. Investors should watch for execution on RadarST and Pantracer LBX launches, as well as the impact of LIMS integration on margin trajectory.
Summary
- NGS Momentum Redefines Growth: Shift to high-value NGS and MRD testing is driving revenue mix and margin upside.
- Strategic Volume Rationalization: Exiting low-value contracts positions NeoGenomics for profitable, sustainable growth.
- 2026 Inflection Point: Operational leverage and new product launches set the stage for accelerated earnings power in 2027 and beyond.
Performance Analysis
NeoGenomics delivered record quarterly revenue on the back of robust clinical business expansion, with clinical revenue up double digits and NGS (next-generation sequencing, high-throughput genetic testing) revenue surging 23% year-over-year. The company’s clinical segment now accounts for the majority of total revenue, with NGS products contributing roughly a third of clinical sales—a mix shift that is structurally raising average unit price (AUP) and gross margin potential.
Non-clinical revenue (primarily pharma services) continued its anticipated decline, down over 25% for the quarter and 24% for the year, reflecting ongoing industry headwinds and NeoGenomics’ strategic focus on higher-margin clinical growth. Gross margin compressed in 2025, primarily due to the Pathline acquisition and new product launch costs, but management signaled a return to margin expansion in 2026 as higher-value tests scale and operational efficiencies take hold. Positive cash flow from operations and sequential EBITDA margin improvement underscore strong financial discipline.
- NGS Outperformance: NGS test revenue outpaced market growth, with five new products launched since 2023 now representing 23% of clinical revenue.
- Volume Rationalization: Exiting low-value contracts is intentionally lowering volume growth but boosting AUP and margin profile.
- Operational Leverage: Pathline integration and early LIMS (Laboratory Information Management System, lab workflow software) rollout are expected to deliver incremental margin gains in late 2026 and beyond.
NeoGenomics’ business model is evolving toward a higher-quality revenue base, with the clinical segment and NGS portfolio increasingly central to its long-term value creation.
Executive Commentary
"We are intentionally shifting testing capacity towards more therapy-guided and higher-value testing, which is expected to make AUP expansion a more significant driver of revenue growth relative to volume."
Tony Zook, Chief Executive Officer
"Most of our margin expansion in the current year, in 2026, is going to be coming from the gross margin. So we are anticipating the growth margins to expand at about 100 basis points."
Abhishek Jain, EVP of Finance & Incoming CFO
Strategic Positioning
1. Clinical Channel Penetration and Community Focus
NeoGenomics’ commercial strategy is centered on the community oncology setting, where 80% of cancer care is delivered and innovation adoption lags. The company’s broad test menu, ease of ordering, and fast turnaround times have enabled it to capture over 25% share in hematology and drive 14% growth in multi-test ordering providers. Net Promoter Score (NPS) of 79 highlights strong physician loyalty and supports continued share gains.
2. High-Value Product Innovation: RadarST and Pantracer Portfolio
RadarST, MRD (minimal residual disease, cancer recurrence detection) assay, is set for full clinical launch, with initial focus on HPV-negative head and neck and select breast cancer indications. Additional MoldDX submissions are pending, with management expecting further approvals in late 2026 that could double the eligible patient pool. The Pantracer portfolio, including new LBX (liquid biopsy) and Pro offerings, is broadening NeoGenomics’ solid tumor therapy selection reach and driving incremental clinical revenue.
3. Volume Quality Over Quantity
Deliberate exit from low-margin, high-volume contracts is shifting growth mix toward AUP expansion, with NGS and therapy selection tests commanding higher prices and supporting margin improvement. Management expects AUP growth in the upper single digits, with volume growth moderating as the business prioritizes profitable segments.
4. Operational Efficiency and LIMS Integration
Migration to a unified LIMS platform is foundational for future margin expansion, enabling workflow optimization, real-time analytics, and improved customer experience. While benefits will be incremental in 2026, full impact is expected in 2027 and beyond as legacy systems are retired and automation initiatives scale.
5. Pharma Segment Stabilization
Pharma services remain a small but strategically relevant segment (5-6% of revenue), with management anticipating modest erosion in 2026 and a return to growth in 2027, driven by RadarST adoption. Strategic focus is on therapy selection and MRD, aligning with clinical growth vectors.
Key Considerations
This quarter marks a structural pivot in NeoGenomics’ growth model, with management executing a deliberate shift from volume-led to value-led revenue expansion. The following considerations are central for investors:
Key Considerations:
- NGS and MRD Scaling: Continued outperformance in NGS and the commercial launch of RadarST are critical levers for revenue and margin acceleration.
- Sales Force Productivity: Recent expansion and maturation of the oncology sales specialist team is driving increased test penetration and multi-product adoption in community accounts.
- Operational Leverage: Pathline integration and LIMS migration are expected to unlock cost efficiencies and margin expansion, though full benefits will phase in over several years.
- Reimbursement and Coverage: MoldDX approval timing for new indications (especially Pantracer LBX) remains a key swing factor for 2026 upside.
- Clinical Volume Mix: Management’s focus on high-value tests may suppress headline volume growth but will enhance profitability and earnings quality.
Risks
Key risks include reimbursement delays for new products, ongoing pharma services headwinds, and execution risk around LIMS integration and sales force expansion. Competitive intensity in both tissue and liquid biopsy markets remains high, and any setbacks in product adoption or coverage approvals could pressure both growth and margins. Management’s prudent guidance reflects these uncertainties, but upside is contingent on timely execution and favorable regulatory outcomes.
Forward Outlook
For Q1 2026, NeoGenomics expects:
- Year-over-year revenue growth of approximately 10%, moderating due to seasonality and volume rationalization.
- Weather-related office closures to impact Q1 volumes, already reflected in full-year guidance.
For full-year 2026, management guides to:
- Total revenue of $793 million to $801 million, embedding modest contributions from RadarST and Pantracer LBX in the back half.
- Adjusted EBITDA of $55 million to $57 million, reflecting 27-31% growth and gross margin expansion of 100-120 basis points.
Management highlighted:
- Back-half weighting of new product contributions as MoldDX approvals and sales force expansion ramp.
- Continued investment in sales, R&D, and technology to support long-term growth and margin improvement.
Takeaways
NeoGenomics is executing a high-quality growth transition, with NGS and MRD at the center of its strategy. Margin expansion is returning as volume rationalization and operational leverage take hold. The next phase of growth hinges on successful RadarST and Pantracer LBX launches and continued community channel penetration.
- NGS and MRD Drive Value: High-value test mix and new product launches are structurally raising AUP and margin potential, offsetting volume headwinds from low-value contract exits.
- Operational Focus Yields Results: Pathline and LIMS integration are laying the groundwork for multi-year efficiency gains, with margin expansion already re-emerging in 2026 guidance.
- Watch Product Launch Execution: Timely MoldDX approvals and effective sales force deployment will determine the pace and magnitude of 2026 and 2027 growth inflection.
Conclusion
NeoGenomics’ Q4 and 2025 results confirm a decisive pivot toward high-value, high-margin growth, with NGS and MRD scaling rapidly and operational discipline supporting margin recovery. 2026 is a transition year, with the real earnings power set to emerge as new products and efficiency programs reach scale.
Industry Read-Through
NeoGenomics’ results underscore the accelerating shift in oncology diagnostics toward high-complexity, high-reimbursement testing (NGS, MRD, liquid biopsy) and the importance of channel penetration in community oncology. Strategic volume rationalization and operational leverage are becoming critical for sustainable profitability, signaling that scale alone is no longer enough for diagnostics players. Competitors and adjacent labs should note the rising bar for commercial execution, reimbursement navigation, and workflow integration as key differentiators in the evolving oncology testing landscape.